SK285250B6 - Orálna farmaceutická kompozícia obsahujúca rivastigmín a použitie rivastigmínu - Google Patents

Orálna farmaceutická kompozícia obsahujúca rivastigmín a použitie rivastigmínu Download PDF

Info

Publication number
SK285250B6
SK285250B6 SK439-2001A SK4392001A SK285250B6 SK 285250 B6 SK285250 B6 SK 285250B6 SK 4392001 A SK4392001 A SK 4392001A SK 285250 B6 SK285250 B6 SK 285250B6
Authority
SK
Slovakia
Prior art keywords
rivastigmine
component
minutes
water
film
Prior art date
Application number
SK439-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK4392001A3 (en
Inventor
J�Rg Ogorka
Oskar Kalb
Rajen Shah
Satish Chandra Khanna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285250(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821299.6A external-priority patent/GB9821299D0/en
Priority claimed from GBGB9821298.8A external-priority patent/GB9821298D0/en
Priority claimed from GBGB9826654.7A external-priority patent/GB9826654D0/en
Priority claimed from GBGB9827624.9A external-priority patent/GB9827624D0/en
Priority claimed from GBGB9907822.2A external-priority patent/GB9907822D0/en
Priority claimed from GBGB9907823.0A external-priority patent/GB9907823D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK4392001A3 publication Critical patent/SK4392001A3/sk
Publication of SK285250B6 publication Critical patent/SK285250B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK439-2001A 1998-10-01 1999-10-01 Orálna farmaceutická kompozícia obsahujúca rivastigmín a použitie rivastigmínu SK285250B6 (sk)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9821299.6A GB9821299D0 (en) 1998-10-01 1998-10-01 Organic compounds
GBGB9821298.8A GB9821298D0 (en) 1998-10-01 1998-10-01 Organic compoundsq
GBGB9826654.7A GB9826654D0 (en) 1998-12-03 1998-12-03 Organic compounds
GBGB9827624.9A GB9827624D0 (en) 1998-12-16 1998-12-16 Organic compounds
GBGB9907822.2A GB9907822D0 (en) 1999-04-06 1999-04-06 Organic compounds
GBGB9907823.0A GB9907823D0 (en) 1999-04-06 1999-04-06 Organic compounds
PCT/EP1999/007298 WO2000019985A2 (en) 1998-10-01 1999-10-01 New sustained release oral formulations

Publications (2)

Publication Number Publication Date
SK4392001A3 SK4392001A3 (en) 2002-07-02
SK285250B6 true SK285250B6 (sk) 2006-09-07

Family

ID=27547321

Family Applications (1)

Application Number Title Priority Date Filing Date
SK439-2001A SK285250B6 (sk) 1998-10-01 1999-10-01 Orálna farmaceutická kompozícia obsahujúca rivastigmín a použitie rivastigmínu

Country Status (23)

Country Link
US (5) US20010033866A1 (de)
EP (1) EP1121104B1 (de)
JP (1) JP4012689B2 (de)
KR (1) KR100603900B1 (de)
CN (1) CN1406126A (de)
AT (1) ATE286725T1 (de)
AU (1) AU764866B2 (de)
BR (1) BR9914251A (de)
CA (1) CA2342340C (de)
CZ (1) CZ302888B6 (de)
DE (1) DE69923200T2 (de)
ES (1) ES2237163T3 (de)
HK (1) HK1052473A1 (de)
HU (1) HUP0103883A3 (de)
ID (1) ID27504A (de)
IL (2) IL141762A0 (de)
NO (1) NO331689B1 (de)
NZ (1) NZ510683A (de)
PL (1) PL196945B1 (de)
PT (1) PT1121104E (de)
SK (1) SK285250B6 (de)
TR (1) TR200100931T2 (de)
WO (1) WO2000019985A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27504A (id) * 1998-10-01 2001-04-12 Novartis Ag Formulasi oral baru
AU1738800A (en) * 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EP1206250A2 (de) * 1999-08-26 2002-05-22 ELAN CORPORATION, Plc Pharmazeutische zusammensetzungen mit verschiedener wirkstoffabgabezeit
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
KR100833469B1 (ko) * 2000-09-29 2008-05-29 솔베이 파마슈티칼스 비. 브이 이온 농도에 비의존적인 지속 방출성 약제학적 제형
JP5023412B2 (ja) * 2001-05-09 2012-09-12 吉澤石灰工業株式会社 ホルムアルデヒド廃液の処理剤
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
DE60223695T2 (de) * 2001-09-14 2008-10-30 Scolr, Inc., Redmond Aminosäure-modulierte dosierform mit verlängerter freisetzung
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
DE60328198D1 (de) * 2002-08-07 2009-08-13 Novartis Ag Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
PL196544B1 (pl) * 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
US20100129310A1 (en) * 2004-08-09 2010-05-27 Pavak Rajnikanth Mehta Stabilized desloratadine composition
EP1909770B1 (de) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Kontrolliert freigesetzte, orale zusammensetzung mit levetiracetam
CA2606740A1 (en) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Quinine-containing controlled-release formulations
KR100990590B1 (ko) * 2005-09-01 2010-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 붕해성이 개선된 의약 조성물의 제조 방법
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
EP2019679B1 (de) 2006-05-23 2018-06-20 Theracos, Inc. Glucosetransporthemmer und anwendungsverfahren
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US7838498B2 (en) 2007-04-02 2010-11-23 Theracos, Inc. Benzylic glycoside derivatives and methods of use
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
UA99924C2 (en) 2007-08-23 2012-10-25 Теракос, Инк. Benzylbenzol derivatives and using thereof
US20100204303A1 (en) * 2007-09-25 2010-08-12 Idexx Laboratories, Inc. Pharmaceutical Compositions for Administering Oligonucleotides
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
TWI441831B (zh) 2008-08-22 2014-06-21 Theracos Inc 製備ｓｇｌｔ２抑制劑之方法
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
MX2012003207A (es) 2009-09-18 2012-05-29 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
JP6086326B2 (ja) 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2675893B1 (de) 2011-02-18 2019-01-09 The Scripps Research Institute Gezielte differenzierung von oligodendrozyten-vorläuferzellen für ein myelinierungs-zellschicksal
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
BR112013028668A2 (pt) * 2011-05-06 2017-01-24 Glaxosmithkline Llc formulações de paracetamol de liberação sustentada
AU2012256501B2 (en) * 2011-05-13 2017-04-06 Eb Ip Hybritabs B.V. Drug delivery system
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
MX354547B (es) 2011-11-14 2018-03-09 Alfasigma Spa Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión.
BR112015004902A2 (pt) 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
KR20190036370A (ko) 2017-09-27 2019-04-04 서원대학교산학협력단 약물의 서방성 제형을 위한 약물전달체
PL3829551T3 (pl) 2018-07-30 2024-04-02 Biothea Pharma, Inc. Krystaliczna sól malonianu epinefryny
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9701695D0 (en) 1997-01-28 1997-03-19 De Beers Ind Diamond Insert for an abrasive tool
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
WO1998053802A1 (en) * 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
ID27504A (id) * 1998-10-01 2001-04-12 Novartis Ag Formulasi oral baru
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders

Also Published As

Publication number Publication date
NZ510683A (en) 2003-09-26
IL141762A (en) 2010-06-30
ES2237163T3 (es) 2005-07-16
DE69923200D1 (de) 2005-02-17
AU764866B2 (en) 2003-09-04
PL348734A1 (en) 2002-06-03
KR20010073168A (ko) 2001-07-31
DE69923200T2 (de) 2005-12-22
US20050175706A1 (en) 2005-08-11
WO2000019985A2 (en) 2000-04-13
HUP0103883A2 (hu) 2002-05-29
EP1121104A2 (de) 2001-08-08
US20030203025A1 (en) 2003-10-30
PL196945B1 (pl) 2008-02-29
CZ20011155A3 (cs) 2001-08-15
EP1121104B1 (de) 2005-01-12
AU6332199A (en) 2000-04-26
CZ302888B6 (cs) 2012-01-11
JP4012689B2 (ja) 2007-11-21
PT1121104E (pt) 2005-05-31
CN1406126A (zh) 2003-03-26
NO331689B1 (no) 2012-02-27
HUP0103883A3 (en) 2002-11-28
KR100603900B1 (ko) 2006-07-25
BR9914251A (pt) 2001-06-19
US20030039692A1 (en) 2003-02-27
NO20011471D0 (no) 2001-03-22
HK1052473A1 (zh) 2003-09-19
TR200100931T2 (tr) 2001-10-22
WO2000019985A3 (en) 2000-07-20
CA2342340C (en) 2006-08-29
US20010033866A1 (en) 2001-10-25
ID27504A (id) 2001-04-12
JP2002526402A (ja) 2002-08-20
US20070053982A1 (en) 2007-03-08
IL141762A0 (en) 2002-03-10
SK4392001A3 (en) 2002-07-02
US6565883B2 (en) 2003-05-20
CA2342340A1 (en) 2000-04-13
ATE286725T1 (de) 2005-01-15
NO20011471L (no) 2001-03-22

Similar Documents

Publication Publication Date Title
SK285250B6 (sk) Orálna farmaceutická kompozícia obsahujúca rivastigmín a použitie rivastigmínu
US20030133982A1 (en) Zero-order sustained release dosage forms and method of making same
US20110038897A1 (en) Oral controlled release formulations
WO2005084636A2 (en) A process for the preparation of controlled-release pharmaceutical composition of metoprolol
RU2286766C2 (ru) Новые композиции пролонгированного действия для перорального введения
MXPA01002365A (en) New sustained release oral formulations
ZA200101932B (en) New sustained release oral formulations

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20131001